These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 11281386)

  • 1. Allogeneic peripheral blood stem cell transplantation results in less alteration of early T cell compartment homeostasis than bone marrow transplantation.
    Tayebi H; Tiberghien P; Ferrand C; Lienard A; Duperrier A; Cahn JY; Lapierre V; Saas P; Kuentz M; Blaise D; Hervé P; Robinet E;
    Bone Marrow Transplant; 2001 Jan; 27(2):167-75. PubMed ID: 11281386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model.
    Hartung G; Zeis M; Glass B; Dreger P; Steinmann J; Schmitz N; Uharek L
    Bone Marrow Transplant; 2003 Jul; 32(1):49-56. PubMed ID: 12815478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor.
    Arseniev L; Tischler HJ; Battmer K; Südmeier I; Casper J; Link H
    Bone Marrow Transplant; 1994 Nov; 14(5):791-7. PubMed ID: 7534162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation.
    Siegert W; Beyer J; Kingreen D; Blasczyk R; Baurmann H; Schwella N; Schleicher J; Kirsch A; Huhn D
    Bone Marrow Transplant; 1998 Sep; 22(6):579-83. PubMed ID: 9758347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Reconstitution of peripheral blood lymphocytes in patients treated with bone marrow transplantation: comparison between allogeneic and autologous transplantation].
    Parra C; Roldán E; Rodríguez C; Pérez de Oteyza J; Oteho E; López J; Maldonado MS; García Laraña J; Muñoz A; Odriozola J; Brieva JA
    Med Clin (Barc); 1999 Jun; 113(1):1-5. PubMed ID: 10422068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome.
    Russell JA; Larratt L; Brown C; Turner AR; Chaudhry A; Booth K; Woodman RC; Wolff J; Valentine K; Stewart D; Ruether JD; Ruether BA; Klassen J; Jones AR; Gyonyor E; Egeler M; Dunsmore J; Desai S; Coppes MJ; Bowen T; Anderson R; Poon MC
    Bone Marrow Transplant; 1999 Dec; 24(11):1177-83. PubMed ID: 10642805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transition of T cell receptor gamma/delta expressing double negative (CD4-/CD8-) lymphocytes after allogeneic bone marrow transplantation.
    Yabe M; Yabe H; Hattori K; Hinohara T; Morimoto T; Kato S; Kusunoki A
    Bone Marrow Transplant; 1994 Nov; 14(5):741-6. PubMed ID: 7889006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
    Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
    Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low incidence of severe aGVHD and accelerating hemopoietic reconstitution in allo-BMT using lenograstim stimulated BM cells.
    Ji S; Chen H; Wang H; Ma J; Pan S; Xue M; Zhu L; Liu J; Xiao M; Zhou L
    Chin Med J (Engl); 2001 Feb; 114(2):191-5. PubMed ID: 11780205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapeutic aspects of allogeneic peripheral progenitor cells.
    Glass B; Uharek L; Hartung G; Zeis M; Steinmann J; Dreger P; Krönke M; Schmitz N
    Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S3-8. PubMed ID: 9712483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
    Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome.
    Barge RM; Brouwer RE; Beersma MF; Starrenburg CW; Zwinderman AH; Hale G; Waldmann H; den Ottolander GJ; Falkenburg JH; Willemze R; Fibbe WE
    Bone Marrow Transplant; 2001 May; 27(10):1053-8. PubMed ID: 11438820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective comparison of immune reconstitution in pediatric recipients of positively selected CD34+ peripheral blood stem cells from unrelated donors vs recipients of unmanipulated bone marrow from related donors.
    Eyrich M; Leiler C; Lang P; Schilbach K; Schumm M; Bader P; Greil J; Klingebiel T; Handgretinger R; Niethammer D; Schlegel PG
    Bone Marrow Transplant; 2003 Aug; 32(4):379-90. PubMed ID: 12900774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymus-independent expansion of T lymphocytes in children after allogeneic bone marrow transplantation.
    Honda K; Takada H; Nagatoshi Y; Akazawa K; Ohga S; Ishii E; Okamura J; Hara T
    Bone Marrow Transplant; 2000 Mar; 25(6):647-52. PubMed ID: 10734299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation.
    Huang X; Guo N; Ren H; Zhang Y; Gao Z; Lu D
    Chin Med J (Engl); 2003 May; 116(5):736-41. PubMed ID: 12875692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
    Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
    Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
    Gadisseur AP; Gratama JW; Lamers C; van Esser JW; Bolhuis RL; Cornelissen JJ
    Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.